id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-3464-0029,FDA,FDA-2016-N-3464,"List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act",Rule,Final Rule,2019-02-19T05:00:00Z,2019,2,2019-02-19T05:00:00Z,,2019-02-19T14:46:18Z,2019-02367,0,0,0900006483a88bb0
FDA-2016-N-3464-0033,FDA,FDA-2016-N-3464,"Reference 16 - Food and Drug Administration Supplemental Review of Topical Tranilast, April 25, 2016.",Supporting & Related Material,Background Material,2019-02-19T05:00:00Z,2019,2,,,2019-02-19T19:50:14Z,,0,0,0900006483a8baf0
FDA-2016-N-3464-0030,FDA,FDA-2016-N-3464,"Reference 3 - Memorandum to File on Food and Drug Administration Consultations with United States Pharmacopeia, September
26, 2016.",Supporting & Related Material,Background Material,2019-02-19T05:00:00Z,2019,2,,,2019-02-19T19:44:10Z,,0,0,0900006483a8baed
FDA-2016-N-3464-0031,FDA,FDA-2016-N-3464,"Reference 4 - Letter from the United States Pharmacopeia to FDA, October 7, 2016.",Supporting & Related Material,Background Material,2019-02-19T05:00:00Z,2019,2,,,2019-02-19T19:46:13Z,,0,0,0900006483a8baee
FDA-2016-N-3464-0032,FDA,FDA-2016-N-3464,"Reference 10 - Food and Drug Administration Supplemental Review of Oxitriptan, November 2018.",Supporting & Related Material,Background Material,2019-02-19T05:00:00Z,2019,2,,,2019-02-19T19:48:01Z,,0,0,0900006483a8baef